TY  - JOUR
T1  - NEtilmicin in the treatment of infections in patients with cancer
AU  - Yap B, Bodney GP
Y1  - 1979/11/01
N1  - 10.1001/archinte.1979.03630480043015
JO  - Archives of Internal Medicine
SP  - 1259
EP  - 1262
VL  - 139
IS  - 11
N2  - Ninety-two patients with cancer with 100 infectious episodes were treated with netilmicin sulfate, a new aminoglycoside. Netilmicin was administered intravenously, either intermittently or by continuous infusion. The overall cure rate was 60%. Gram-negative bacilli were the most common causative organisms and the response rate for these infections was 32/53 (60%). The most common pathogens were Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Pneumonia, urinary tract infection, and septicemia were the most common types of infection treated and the response rates were 23/47 (49%), 19/21 (90%), and 9/17 (53%), respectively. Nephrotoxicity occurred in ten patients (6%) who had normal renal function initially. Netilmicin is an effective aminoglycoside with a spectrum of antibacterial activity similar to that of gentamicin sulfate and it appears to be less nephrotoxic.(Arch Intern Med 139:1259-1262, 1979)
SN  - 0003-9926
M3  - doi: 10.1001/archinte.1979.03630480043015
UR  - http://dx.doi.org/10.1001/archinte.1979.03630480043015
ER  -